Recent Updates
Recently added Catalysts
AMGN Positive Sentiment

IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Tuesday, September 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Amgen announced that the Phase 3 DeLLphi-305 study demonstrated a significant improvement in overall survival for IMDELLTRA® in combination with IMFINZI® compared to durvalumab alone. The study also successfully met secondary endpoints, including progression-free survival and objective response rate, marking a notable advancement in treatment for extensive stage small cell lung cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • IMDELLTRA® showed significant improvement in overall survival.
  • The study met secondary endpoints for progression-free survival.
  • Clinically meaningful results were achieved in extensive stage small cell lung cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Maridebart cafraglutide
Phase 3 · Obesity Disease

Full Press Release Details

Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone Study Also Met Secondary Progression-Free Survival and Objective Response Rate Endpoints THOUSAND OAKS, Calif., Sept. 8, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today

Frequently Asked Questions

What was the main finding of the DeLLphi-305 study?

The study found that IMDELLTRA® combined with IMFINZI® significantly improved overall survival.

What secondary endpoints were met in the study?

The study met secondary endpoints for progression-free survival and objective response rate.

What type of cancer was targeted in this study?

The study focused on extensive stage small cell lung cancer.

Who conducted the DeLLphi-305 study?

The study was conducted by Amgen.

ShareAdd on Google
Tags: AMGN Viatris Investor Conferences Healthcare IMDELLTRA IMFINZI small cell lung cancer overall survival
Last updated: Sep 8, 2026

Biotech snapshot

Cash runway
$27404M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Maridebart cafraglutidePhase 3
Obesity Disease →

Catalyst track record

+30%
best trade around AMGN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for AMGN.

See every catalyst's timing & PoA →